Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Males and females meeting 2009 RIS criteria~2. Identified RIS cases with the initial MRI demonstrating anomalies suggestive of demyelinating disease dated \> 2009~3. Incidental anomalies identified on MRI of the brain or spinal cord with the primary reason for the acquired MRI resulting from an evaluation of a process other than MS~4. CNS white matter anomalies meeting the following MRI criteria:~   * Ovoid, well-circumscribed, and homogeneous foci with or without involvement of the corpus callosum~  * T2-hyperintensities measuring \> 3mm2 and fulfilling 3 of 4 Barkhof-Tintoré criteria for dissemination in space~  * CNS anomalies not consistent with a vascular pattern~  * Qualitative determination that CNS anomalies have a characteristic appearance of demyelinating lesions~5. MRI anomalies do not account for clinically apparent neurological impairments in patients~Exclusion criteria~1. Women who are pregnant or nursing~2. Incomplete medical history or radiological data~3. History of remitting clinical symptoms consistent with multiple sclerosis lasting \> 24 hours prior to CNS imaging revealing anomalies suggestive of MS~4. History of paroxysmal symptoms associated with MS (i.e. Lhermitte's or Uhthoff's phenomena)~5. CNS MRI anomalies are better accounted for by another disease process~6. The subject is unwilling or unable to comply with the requirements of the study protocol~7. Exposure to a disease modifying therapy for MS/RIS within the past 3 months~8. Exposure to high-dose glucocorticosteroid treatment within the past 30 days~9. Participation in other clinical trials involving treatment with a disease-modifying agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tecfidera (Type: ACTIVE_COMPARATOR): Tecfidera (120mg by mouth twice daily for 7 days with dose escalation to 240mg by mouth twice daily)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo by mouth twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).